Finally moving forward

The American Medical Association (AMA) has finally shifted from fighting ICD-10 implementation to efforts to help physicians be ready in time for the Oct. 1 deadline.

The switch came as a result of the Centers for Medicare & Medicaid Services (CMS) agreeing not to deny claims with coding errors for the first year of ICD-10, cutting quality reporting requirements, taking steps to reduce payment disruption and setting up a communications center to triage coding issues.

AMA now wants to make sure providers are ready for ICD-10 and will work with CMS to provide education through webinars, on-site training, educational articles and national provider calls to help physicians and other healthcare providers learn about the updated codes and prepare for the transition.

Providers seem to be well on the way to preparing for the change in codesets: CMS announced this week that it accepted 90 percent of submitted claims during the latest and third ICD-10 end-to-end testing week last month.

The testing occurred from June 1 through June 5 during which 1,238 voluntary participants submitted more than 13,000 claims.

Of the rejected claims, CMS found the reasons for rejections were unrelated to ICD-10. For example, rejected claims errors include invalid national provider identifier, invalid beneficiary number, invalid or missing ZIP code or invalid Healthcare Common Procedure Coding System code.

Could we really have reached a point in which rigorous debate about ICD-10 implementation has come to an end?

Beth Walsh

Clinical Innovation + Technology editor

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.